The global landscape for therapeutics targeting IgG4-related disease is experiencing substantial development. Driven by an rising prevalence of these immunological conditions and the presence of novel treatment solutions, the market is poised for remarkable potential in the upcoming future. Key factors propelling this expansion include a increasing